Develop novel therapies for immunology and inflammatory diseases. Focus on chronic fibrotic conditions with significant unmet medical needs. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Our checks did not surface a specific strength to highlight here.
A loss of $70.0M against $0 in annual sales.
At the current pace of spending, the cash lasts about 1.9 years. After that, the company needs to find new money.
Not scored: this is a debt/preferred or other non-common instrument, or its reported market value does not match its share basis.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown, the price history.